????如果，假設地說，阿特維斯不久被Valeant收購，那么阿特維斯在500強榜單的停留時間就很短了。那樣會不會有點失望？比薩羅回答說：“我們希望長期留在榜單上。”

????比薩羅在幾個月前剛完成了自身的一個重要收購計劃。去年10月31日，華生制藥宣布對瑞士阿特維斯集團的收購完成，這次收購以55億美元股票加現金的方式交易。新合并后的公司名叫阿特維斯，而不是華生。（為了給這次收購交易融資，公司資產負債表上增加了60億美元債務。目前的債務與息稅折舊及攤銷前利潤比率為3.5倍。比薩羅說，考慮到公司強勁的現金流，這個比率水平完全可控。）這次收購使阿特維斯成為全球第三大仿制藥生產商，業務布局于全球62個國家，而之前為20個。比薩羅對我說：“我們現在能切實說阿特維斯是個全球公司。”

????用阿特維斯這個名字是有道理的，比薩羅說，因為“華生”這個名字在全球太普通了，而且公司在澳大利亞和英國市場曾與相似命名的企業發生過版權糾紛。但阿特維斯沒有對改名掉以輕心，它之前聘請了品牌策略公司Lippincott研究各種選項，咨詢師們最初提供了近2000種方案。（其中一個內部建議是，用華生和阿特維斯的組合出一個名稱：“Wacktivis”，這個建議很快被否定。）比薩羅和他的團隊將范圍縮小到8個備選名字，最后決定使用阿特維斯，這個名字的全球識別度已經相當高，是最好不過的選擇。

????阿特維斯已經在全球成功進行了改名，唯一的例外是他們在帕西帕尼的花園式總部。停車場和大樓的外面的所有指示牌都還寫著“華生制藥”。當然，在幾年前，比薩羅計劃把總部從加利福尼亞的科洛納搬到帕西帕尼時，花了兩年時間才獲得帕西帕尼同意將帶有公司名字字樣的指示牌樹立起來。標識更改之戰很可能在并購整合完成后繼續很長時間。最初，聯席創始人趙天宇（臺裔美籍）給這家制藥公司命名為華生。趙天宇為了紀念母親，在1984年成立公司時，用母親的娘家姓“華”來命名。華生，即“華”之子。趙天宇在2007年退休之前一直擔任CEO一職，隨后由比薩羅繼任。

????比薩羅，現年52歲，1992年進入制藥業，當時他是巴爾制藥（Barr Pharmaceuticals）的首席法律顧問，后來升職為總裁兼首席運營官。在他剛加入華生時，便將全球擴張作為重中之重。當時，公司幾乎所有的收入都來自于美國市場。今年，阿特維斯約40%的銷售額將來自于美國境外。比薩羅預計，在5年內，美國鏡內外銷售比將達到1：1。阿特維斯在全球的雇員數量為1萬7千人，包括在美國的約5400名員工，在印度有龐大生產業務。

????如今，所有仿制藥生產商目前都面臨著一個重大挑戰：仿制藥依靠暢銷品牌藥的專利過期帶動業務，而專利過期潮近年來正在逐漸退去。比薩羅稱，下一個大機遇是所謂的生物仿制藥——即昂貴的尖端生物藥品的基本仿制品，而生物藥品銷量已經開始趕超傳統小顆粒藥品。比薩羅將生物仿制藥稱為“新前沿領域”。阿特維斯已經和生物科技巨頭安進（Amgen）達成協議，在安進的四款藥品專利到期后，進行共同銷售。比薩羅說他相信阿特維斯能在這個新領域不斷增長。

????如果比薩羅是正確的，阿特維斯便能繼續留在500強的榜單上，并且一路向上攀登。他說：“我們不會只滿足于432位，還想排名更靠前?！?/p>

????從某種程度上說，排名靠前帶來的聲望或許也能幫助他更改大樓的標識。（財富中文網）

????譯者：默默

????If, hypothetically, Actavis were to be acquired by Valeant in the near future, that would make for a very short stay for Actavis on the 500. Wouldn't that be kind of a letdown? "Our intention is to be on the Fortune 500 for a long time," replied Bisaro tactfully.

????It's only been a few months since Bisaro completed a major purchase of his own. On Oct. 31, Watson Pharmaceutical announced that its $5.5 billion stock and cash deal to buy the Actavis Group of Switzerland had closed, and that the newly-merged company would be known as Actavis, not Watson. (To fund the purchase, the company put about $6 billion of debt on its balance sheet. It's now at 3.5 times debt-to-EBITDA, which Bisaro says is easily manageable given its strong cash flow.) The deal made Actavis the world's third-largest generic drugmaker. It now operates in 62 countries, up from 20. "We can truly say we're a global company now," Bisaro told me.

????Taking the Actavis name made sense, said Bisaro, because "Watson" turned out to be too common around the world, and he ran into copyright conflicts with similarly named businesses in markets such as Australia and England. But the company didn't take the name change lightly. It hired brand strategy firm Lippincott to explore options, and the consultants came back with roughly 2,000 possibilities. (One internal suggestion that was quickly rejected was a Watson/Actavis mash-up: "Wacktivis.") Bisaro and his team whittled down the list to eight finalists before deciding that embracing Actavis, already recognized globally, was the best solution.

????Actavis has successfully rebranded itself everywhere already except its own office park headquarters in Parsippany. All the signage in the parking lot and on the outside of the building still reads "Watson Pharmaceuticals." Of course, it took two years for the company to get permission from the local township to put the name up when they moved in a few years ago, after Bisaro moved the headquarters from Corona, Calif. The battle to change the sign may well rage on well after the merger integration is a distant memory.The drugmaker was originally given the name Watson by co-founder Allen Chao, a Taiwanese-American. He wanted to honor his mother, whose maiden name was Hwa. So he Americanized "Hwa's son" into Watson when he started the firm in 1984. Chao served as CEO until he retired in 2007, and Bisaro was recruited to be his successor.

????Bisaro, 52, got into the world of pharma when he joined Barr Pharmaceuticals in 1992 as chief legal counsel, later rising to become president and chief operating officer. When he arrived at Watson, he immediately decided that a top priority was to expand internationally. At the time, almost 100% of the drugmaker's revenues were derived from the U.S. This year about 40% of sales at Actavis will come from outside the U.S., and Bisaro thinks that in five years the ratio of U.S. to non-U.S. revenues could be 50/50. Of the company's 17,000 employees, about 5,400 are in the U.S. It has large production operations in India.

????All generic drugmakers are dealing with a major business challenge these days: The wave of patent expirations on best-selling, branded drugs that fueled their business in recent years is slowing. The next big opportunity, according to Bisaro, is in so-called biosimilars -- basically, generic versions of the complex, expensive biotech medicines that have begun to overtake traditional small molecule pharmaceuticals in sales. Bisaro calls biosimilars "the new frontier." Actavis has signed a deal with biotech giant Amgen (AMGN) to partner in selling four of its drugs as they come off patent. The CEO says he is confident that Actavis is set to keep growing in this brave new world.

????If Bisaro is right, Actavis could become a fixture on the 500, climbing its way toward the top. "We don't just want to be 432," he said. "We want to go up higher."

????At some point, maybe he'll even have enough cred to get the sign changed on his building.